Beta Drugs Limited (BETA) — Board Meeting | 20 July 2026

Beta Drugs Limited announced its Q1FY27 results on 20 July 2026, reporting consolidated revenue of ₹127.13 crores, up 25.3% YoY, with consolidated net profit rising 40.9% to ₹16.5 crores. The board approved the unaudited financial results and associated review reports under SEBI Regulation 33. Management highlighted strong growth in branded oncology, CMO, and export segments, with EBITDA margins expanding to 23.06% including other income. The company reaffirmed its FY27 growth outlook of 20-25% and long-term vision of >80% turnover from high-margin businesses by 2030.